Izotropic Unveils Izoview Commercial Prototype, Files New Patents
Izotropic Unveils Izoview Commercial Prototype, Files New Patents
Vancouver, British Columbia--(Newsfile Corp. - May 10, 2022) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a company commercializing a dedicated breast CT (computed tomography) imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers, is pleased to unveil the commercial prototype device design that will be used in forthcoming clinical studies for market authorization in the U.S.
温哥华,不列颠哥伦比亚省-(Newsfile Corp.-2022年5月10日)-Izotrotic公司(CSE:以藏)(OTCQB:IZOZF)(FSE:1R3) ("各向同性“或”公司),一家将专门的乳腺CT(计算机断层扫描)成像平台IzoView商业化的公司,该平台用于更准确地检测和诊断乳腺癌,该公司高兴地公布了商业原型设备设计,该设备将用于即将在美国进行的临床研究,以获得市场授权。
A photorealistic 3D animation detailing IzoView's design, functionality, and capabilities is now live on the Company's YouTube channel at the following link:
详细介绍IzoView的设计、功能和功能的照片逼真3D动画现已在该公司的YouTube频道上直播,链接如下:
IzoView has been upgraded and reengineered to deliver a state-of-the-art breast imaging device for the future. The experience and importance for patients, operators, insurance providers, and customers have been further studied in recent months to yield what the Company believes is a design and functionality that, once approved for sale, will drive demand, acceptance, and market uptake.
IzoView经过升级和重新设计,为未来提供了一种最先进的乳房成像设备。近几个月来,对患者、运营商、保险提供商和客户的体验和重要性进行了进一步研究,以产生公司认为一旦获得批准销售将推动需求、接受度和市场吸收的设计和功能。
A key feature of IzoView's design is the development of self-shielding, which results in radiation emitted during imaging being contained within the device itself, protecting the operator and surrounding physical areas. As the Company's first self-shielded design, only the patient's breast being imaged is exposed to radiation. IzoView can be safely operated in a space where protective barriers and lead partitions commonly used for CT imaging devices to protect the operator and surrounding area from radiation exposure are not always required.
IzoView设计的一个关键特征是开发了自我屏蔽,这使得成像过程中发射的辐射被包含在设备本身中,保护操作员和周围的物理区域。作为该公司的第一个自我屏蔽设计,只有被成像的患者的乳房暴露在辐射中。IzoView可以在这样一个空间中安全地运行,在这个空间中,CT成像设备通常使用的保护屏障和铅隔板并不总是需要保护操作员和周围地区免受辐射照射。
The Company has begun filing patents to protect unique and important features of the IzoView Breast CT System. The Company will co-own these patents with The Regents of the University of California, from which Izotropic has the exclusive worldwide licensing rights to Breast CT, including ten other patents and ongoing patent applications.
该公司已经开始申请专利,以保护IzoView乳房CT系统的独特和重要功能。该公司将与加州大学的董事会共同拥有这些专利,从加州大学董事会获得乳房CT的全球独家许可权,包括其他10项专利和正在进行的专利申请。
ON BEHALF OF THE BOARD
我代表董事会
Investor Relations Contact:
James Berard
Email: jberard@izocorp.com
Cell: 778-228-2314
Toll Free: 1-833-IZOCORP ext.1
投资者关系联系人:
詹姆斯·贝拉德
电子邮件:jberard@izocorp.com
电话:778-228-2314
免费电话:1-833-IZOCORP分机1
Media Inquiries Contact:
Jaclyn Thast
Email: jaclyn@izocorp.com
Toll Free: 1-833-IZOCORP ext.3
媒体问询联系人:
雅克林·塔斯特
电子邮件:Jaclyn@izocorp.com
免费电话:1-833-IZOCORP转3
About Izotropic Corporation
关于Izotroy公司
Izotropic Corporation is the only publicly-traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. To expedite patient and provider access to IzoView, Izotropic's initial clinical study intends to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures. In follow-on clinical studies, Izotropic intends to validate platform applications, including breast screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.
Izotroy公司是唯一一家将专门的乳腺CT成像平台IzoView商业化的上市公司,该平台用于更准确地检测和诊断乳腺癌。为了加快患者和供应商使用IzoView的速度,Izotroy的初步临床研究打算证明诊断性乳房CT成像比诊断性乳房X光检查程序具有更好的性能。在后续的临床研究中,Izotroy公司打算验证平台应用,包括放射学中的乳房筛查、外科肿瘤学中的治疗计划和监测,以及整形和重建外科中的乳房重建和植入监测。
More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.
欲了解有关Izotroy公司的更多信息,请访问公司网站:izocorp.com,或查看公司在SEDAR上的简介:sedar.com。
Forward-Looking Statements
前瞻性陈述
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView is not yet approved for sale.
本文档可能包含“前瞻性陈述”,这些陈述基于对公司管理层、业务的当前估计、假设、预测和预期,以及对公司运营所处的相关市场和经济环境的了解。在可能的情况下,本公司已尝试通过使用下列词语来识别此类信息和陈述:“预期”、“相信”、“设想”、“估计”、“预期”、“打算”、“可能”、“计划”、“预测”、“项目”、“目标”、“潜在”、“将”、“将”、“可能”、“可能”、“应该”、“继续,关于未来事件、趋势或前景或未来经营或财务业绩的任何讨论,“考虑”及其他类似表述及其派生,尽管并不是所有前瞻性表述都包含这些识别词语。这些陈述不是对业绩的保证,涉及难以控制或预测的风险和不确定因素,因此,它们可能导致公司未来活动的结果与此类陈述的内容和影响大不相同。前瞻性陈述仅在作出之日起具有相关性,公司没有义务更新或修改任何前瞻性陈述,以反映新的信息或未来事件或情况的发生,除非法律另有要求。本公司及其股东、高级管理人员和顾问均不对任何人根据本文所含信息采取的任何行动以及任何行动的结果负责,包括但不限于购买或出售公司证券。本文档中的任何内容都不应被视为任何类型的医疗或其他建议。所有图片仅用于说明目的。IzoView尚未获准出售。
To view the source version of this press release, please visit
要查看本新闻稿的源版本,请访问